Literature DB >> 11857404

Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines.

Xavier Declèves1, Anne Fajac, Jacqueline Lehmann-Che, Marcienne Tardy, Claire Mercier, Ilse Hurbain, Jean-Louis Laplanche, Jean-François Bernaudin, Jean-Michel Scherrmann.   

Abstract

The aim of our study was to investigate the functional expression of P-glycoprotein (Pgp) and multidrug resistance-associated proteins (MRPs) in 2 distinct glioma cells (GL15 and 8MG) from patients with glioblastoma multiforme. MDR1 gene and Pgp expression was not detected in either cell line by RT-PCR and Western blotting, respectively. In contrast, MRP1 was detected at both mRNA and protein level in both cell lines, with a higher expression in the 8MG cells that occur predominantly at the cell membrane. Three other MRPs (MRP3, MRP4 and MRP5) were detected by RT-PCR in both cell lines, whereas MRP2 was not expressed. In addition, MRP3 protein was also detected by immunocytochemistry in both GL15 and 8MG cell lines. Indomethacin and probenecid, 2 modulators of MRPs activity, increased the accumulation of vincristine and etoposide, 2 substrates of MRPs, by both cell lines. These modulators also decreased the efflux of vincristine from both cell lines with a more pronounced effect in 8MG cells. In conclusion, our results show functional expression of MRPs leading to a decrease in the intracellular vincristine and etoposide concentrations in human glioblastoma cell lines. Furthermore, our results that exhibit protein expression of MRP1 and MRP3 and gene expression of MRP4 and MRP5 in these 2 glioblastoma cell lines suggest new mechanisms that could lead to a MDR phenotype of tumour cells in patients with glioblastoma multiforme. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857404     DOI: 10.1002/ijc.10135

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 2.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

3.  CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.

Authors:  G Xi; E Hayes; R Lewis; S Ichi; B Mania-Farnell; K Shim; T Takao; E Allender; C S Mayanil; T Tomita
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

Review 4.  Current progress for the use of miRNAs in glioblastoma treatment.

Authors:  Amanda Tivnan; Kerrie Leanne McDonald
Journal:  Mol Neurobiol       Date:  2013-04-28       Impact factor: 5.590

5.  Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma.

Authors:  C Calatozzolo; M Gelati; E Ciusani; F L Sciacca; B Pollo; L Cajola; C Marras; A Silvani; L Vitellaro-Zuccarello; D Croci; A Boiardi; A Salmaggi
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

6.  MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Authors:  Chien-Tsun Kuan; Kenji Wakiya; James E Herndon; Eric S Lipp; Charles N Pegram; Gregory J Riggins; Ahmed Rasheed; Scott E Szafranski; Roger E McLendon; Carol J Wikstrand; Darell D Bigner
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

7.  Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.

Authors:  Xuejun Liu; Dongwei Yao; Cheng Liu; Yunjian Cao; Qiurong Yang; Zhichao Sun; Duo Liu
Journal:  Tumour Biol       Date:  2016-01-05

Review 8.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

9.  Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.

Authors:  J Wolf; T Stranzl; M Filipits; G Pohl; R Pirker; B Leeb; J S Smolen
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

10.  Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide.

Authors:  Lei Chen; Peimin Feng; Shengfu Li; Dan Long; Jingqiu Cheng; Yanrong Lu; Dong Zhou
Journal:  Neurochem Res       Date:  2008-10-21       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.